Home » Investors » Press Releases

AcouSort launches next generation AcouTrap at CYTO 2023

CYTO is organized by the International Society for the Advancement of Cytometry and attended by leading researchers and instrumentation providers within flow cytometry. This year, AcouSort will use the conference to launch the new and much improved AcouTrap system. The conference is held in Montréal, Canada, May 20-24.

The new AcouTrap 3 system comes with improved design and an updated and intuitive software graphical user interface (GUI), which simplifies user workflows. The new design and new software are based on customer feedback from AcouSort’s last generation of AcouTrap.

Along with the upgrades to the AcouTrap system, AcouSort also presents two new trapping units with improved performance. The smaller unit has a capacity of up to 100,000 cells and is designed for minute samples and rare cells, while the enhanced unit has higher throughput and can handle up to 0.5 million cells. Both units allow for gentle, automated handling with minimal cell loss. 

“We see CYTO as a great place to launch our new AcouTrap system as many flow cytometry users working with precious samples and few cells struggle with the sample preparation workflow. The AcouTrap technology provides a robust solution that can significantly improve user workflows by providing high-performance staining and washing of cells before flow cytometry analysis,” says AcouSort’s Commercial Director Agnes Michanek.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company’s products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company’s products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company’s commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company’s research instruments. With the help of the company’s products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank.

AcouSort_PM_CYTO_EN